vTv Therapeutics (VTVT) Income from Continuing Operations: 2014-2025

Historic Income from Continuing Operations for vTv Therapeutics (VTVT) over the last 12 years, with Sep 2025 value amounting to -$10.3 million.

  • vTv Therapeutics' Income from Continuing Operations fell 77.14% to -$10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.4 million, marking a year-over-year decrease of 24.97%. This contributed to the annual value of -$22.7 million for FY2024, which is 12.56% up from last year.
  • Per vTv Therapeutics' latest filing, its Income from Continuing Operations stood at -$10.3 million for Q3 2025, which was down 40.18% from -$7.4 million recorded in Q2 2025.
  • Over the past 5 years, vTv Therapeutics' Income from Continuing Operations peaked at -$841,000 during Q2 2021, and registered a low of -$10.3 million during Q3 2025.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$6.2 million (2025), whereas its average is -$6.6 million.
  • Within the past 5 years, the most significant YoY rise in vTv Therapeutics' Income from Continuing Operations was 83.15% (2021), while the steepest drop was 690.11% (2021).
  • Over the past 5 years, vTv Therapeutics' Income from Continuing Operations (Quarterly) stood at -$9.5 million in 2021, then surged by 35.78% to -$6.1 million in 2022, then climbed by 27.08% to -$4.4 million in 2023, then rose by 0.09% to -$4.4 million in 2024, then plummeted by 77.14% to -$10.3 million in 2025.
  • Its Income from Continuing Operations was -$10.3 million in Q3 2025, compared to -$7.4 million in Q2 2025 and -$6.2 million in Q1 2025.